Overview Financials News + Filings Key Docs Charts Transactions Holdings Ownership Insiders
|
| In millions, except per share items | Jan-02-22 | Jan-03-21 | Dec-29-19 | Dec-30-18 | Dec-31-17 | Jan-01-17 | Jan-03-16 | Dec-28-14 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
| Revenues: |
| Pharmaceutical | 52,080.0 | 45,572.0 | 42,198.0 | 40,734.0 | 36,256.0 | | 31,430.0 | 32,313.0 |
| Medical Devices | 27,060.0 | 22,959.0 | 25,963.0 | 26,994.0 | 26,592.0 | | 25,137.0 | 27,522.0 |
| Consumer | | | | 13,853.0 | 13,602.0 | | 13,507.0 | 14,496.0 |
| Other | 14,635.0 | 14,053.0 | 13,898.0 | | | | | |
| Total revenues | 93,775.0 | 82,584.0 | 82,059.0 | 81,581.0 | 76,450.0 | 71,890.0 | 70,074.0 | 74,331.0 |
| Revenue growth [+] | 13.6% | 0.6% | 0.6% | 6.7% | 6.3% | 2.6% | -5.7% | 4.2% |
| Pharmaceutical | 14.3% | 8.0% | 3.6% | 12.4% | | | -2.7% | 14.9% |
| Medical Devices | 17.9% | -11.6% | -3.8% | 1.5% | | | -8.7% | -3.4% |
| Consumer | | | | 1.8% | | | -6.8% | -1.4% |
| Cost of goods sold | 29,855.0 | 28,427.0 | 27,556.0 | 27,091.0 | 25,439.0 | 21,789.0 | 21,536.0 | 22,746.0 |
| Gross profit | 63,920.0 | 54,157.0 | 54,503.0 | 54,490.0 | 51,011.0 | 50,101.0 | 48,538.0 | 51,585.0 |
| Gross margin | 68.2% | 65.6% | 66.4% | 66.8% | 66.7% | 69.7% | 69.3% | 69.4% |
| Selling, general and administrative | 24,659.0 | 22,084.0 | 22,178.0 | 22,540.0 | 21,520.0 | 20,067.0 | 21,203.0 | 21,954.0 |
| Research and development | 14,714.0 | 12,159.0 | 11,355.0 | 10,775.0 | 10,594.0 | 9,143.0 | 9,046.0 | 8,494.0 |
| EBITDA [+] | 31,937.0 | 27,145.0 | 27,979.0 | 28,104.0 | 24,539.0 | 24,645.0 | 22,035.0 | 25,032.0 |
| EBITDA growth | 17.7% | -3.0% | -0.4% | 14.5% | -0.4% | 11.8% | -12.0% | 8.5% |
| EBITDA margin | 34.1% | 32.9% | 34.1% | 34.4% | 32.1% | 34.3% | 31.4% | 33.7% |
| Depreciation | 2,690.0 | 2,531.0 | 2,509.0 | 2,529.0 | 2,642.0 | 2,554.0 | 2,546.0 | 2,495.0 |
| EBITA | 29,247.0 | 24,614.0 | 25,470.0 | 25,575.0 | 21,897.0 | 22,091.0 | 19,489.0 | 22,537.0 |
| EBITA margin | 31.2% | 29.8% | 31.0% | 31.3% | 28.6% | 30.7% | 27.8% | 30.3% |
| Amortization of intangibles | 4,700.0 | 4,700.0 | 4,500.0 | 4,400.0 | 3,000.0 | 1,200.0 | 1,200.0 | 1,400.0 |
| EBIT [+] | 24,547.0 | 19,914.0 | 20,970.0 | 21,175.0 | 18,897.0 | 20,891.0 | 18,289.0 | 21,137.0 |
| EBIT growth | 23.3% | -5.0% | -1.0% | 12.1% | -9.5% | 14.2% | -13.5% | 11.5% |
| EBIT margin | 26.2% | 24.1% | 25.6% | 26.0% | 24.7% | 29.1% | 26.1% | 28.4% |
| Non-recurring items [+] | 1,152.0 | 428.0 | 1,156.0 | 1,377.0 | 717.0 | 520.0 | 733.0 | 178.0 |
| In-process research & development | 900.0 | 181.0 | 890.0 | 1,126.0 | 408.0 | 29.0 | 224.0 | 178.0 |
| Interest expense, net [+] | 130.0 | 90.0 | -39.0 | 394.0 | 549.0 | 358.0 | 424.0 | 466.0 |
| Interest expense | 183.0 | 201.0 | 318.0 | 1,005.0 | 934.0 | 726.0 | 552.0 | 533.0 |
| Interest income | 53.0 | 111.0 | 357.0 | 611.0 | 385.0 | 368.0 | 128.0 | 67.0 |
| Other income (expense), net | -489.0 | -2,899.0 | -2,525.0 | -1,405.0 | 42.0 | -210.0 | 2,064.0 | 70.0 |
| Pre-tax income | 22,776.0 | 16,497.0 | 17,328.0 | 17,999.0 | 17,673.0 | 19,803.0 | 19,196.0 | 20,563.0 |
| Income taxes | 1,898.0 | 1,783.0 | 2,209.0 | 2,702.0 | 16,373.0 | 3,263.0 | 3,787.0 | 4,240.0 |
| Tax rate | 8.3% | 10.8% | 12.7% | 15.0% | 92.6% | 16.5% | 19.7% | 20.6% |
| Net income | 20,878.0 | 14,714.0 | 15,119.0 | 15,297.0 | 1,300.0 | 16,540.0 | 15,409.0 | 16,323.0 |
| Net margin | 22.3% | 17.8% | 18.4% | 18.8% | 1.7% | 23.0% | 22.0% | 22.0% |
| |
| Basic EPS [+] | $7.93 | $5.59 | $5.72 | $5.70 | $0.48 | $6.04 | $5.56 | $5.80 |
| Growth | 41.9% | -2.2% | 0.2% | 1081.3% | -92.0% | 8.7% | -4.1% | 17.8% |
| Diluted EPS [+] | $7.81 | $5.51 | $5.63 | $5.61 | $0.47 | $5.93 | $5.48 | $5.70 |
| Growth | 41.7% | -2.2% | 0.5% | 1083.9% | -92.0% | 8.3% | -3.9% | 18.6% |
| |
| Dividends per share [+] | $4.19 | $3.98 | $3.75 | $3.54 | $3.32 | $3.15 | $2.95 | $2.76 |
| Growth | 5.3% | 6.2% | 5.9% | 6.6% | 5.5% | 6.8% | 6.9% | 6.6% |
| |
| Shares outstanding (basic) [+] | 2,632.1 | 2,632.8 | 2,645.1 | 2,681.5 | 2,692.0 | 2,737.3 | 2,771.8 | 2,815.2 |
| Growth | 0.0% | -0.5% | -1.4% | -0.4% | -1.7% | -1.2% | -1.5% | 0.2% |
| Shares outstanding (diluted) [+] | 2,674.0 | 2,670.7 | 2,684.3 | 2,728.7 | 2,745.3 | 2,788.9 | 2,812.9 | 2,863.9 |
| Growth | 0.1% | -0.5% | -1.6% | -0.6% | -1.6% | -0.9% | -1.8% | -0.5% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|